Skip to content
Enlicitide / Studies
Synthetic analog · 1,550.8 Da

Enlicitide studies and research data

PepBank has 6 enlicitide studies with results. 5 of them gave enlicitide, with 33 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 33 results and 47 papers. Newer studies from Europe PMC

Results in people
33
100% of 33 results
Results in animals
0
0% of 33 results
Results in lab cells
0
0% of 33 results
From computer models
0
0% of 33 results
The molecule

Enlicitide identity

Identifiers, parent molecule, targets and development stage, from curated data.

Enlicitide is a synthetic macrocyclic peptide that binds PCSK9 and inhibits its interaction with LDL receptors. Lipfendra tablets contain the decanoate salt. The active cation and the formulated salt have different molecular formulas.

Kind
Synthetic analog
Identifiers
ChEMBLCHEMBL6068773 (opens in a new tab)PubChem CID164933665 (opens in a new tab)UNIIR7EZ772VG2 (opens in a new tab)DrugBankDB22580 (opens in a new tab)CAS2407527-14-2IUPHAR13944 (opens in a new tab)
Development
Approved in the US (Lipfendra, 2026)Merck Sharp & Dohme LLCFDA approved Lipfendra in July 2026. Two completed phase 3 trials tested enlicitide decanoate. Lipids registry enrollment is 2,912. The label reports 2,904 treated participants. These denominators differ. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
TargetActionEvidence
PCSK9PCSK9Q8NBP7 (opens in a new tab)InhibitorDailyMed section 12.1 establishes PCSK9 binding and inhibition of the PCSK9-LDLR interaction.Source (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

Sequence not disclosed

The formula, mass, SMILES and InChIKey describe the enlicitide cation, not its decanoate salt. PubChem, ChEMBL and IUPHAR agree on the stereochemical InChIKey. The label gives C92H129FN14O17 and 1722.12 g/mol for enlicitide decanoate. The chemical name specifies both L- and D-residues, two lactam closures and an ether closure. No standard linear sequence, residue count, terminal assignment or HELM was established. Empty modification positions do not imply an unmodified peptide.

Properties

From identity sources

Formula
C82H110FN14O15+
Molecular weight
1,550.8 g/mol
Monoisotopic mass
1,549.8259 Da

Calculated from the sequence

No sequence is listed, so nothing can be calculated.

Net charge by pH

No charge curve

No sequence is listed for this peptide.

Composition

No sequence is listed for this peptide.

3D structure

No 3D structure

No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.

2D structure

Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).

SMILES fromPubChem CID 164933665(opens in a new tab)

C[C@H]1C(=O)N[C@@H](C(=O)N[C@H]2CC3=CC(=CC=C3)CNC(=O)CO[C@H]4CCN5[C@@H]4C(=O)N[C@H](C(=O)N[C@H](C(=O)N6CCC[C@]6(C(=O)NCCC7=CC=C(CN(CCCCCCN8C=C(C[C@@H](C5=O)NC2=O)C9=C8C=CC(=C9)F)C(=O)CCC(=O)N1)C=C7)C)CC1=CC=C(C=C1)OC)[C@@H](C)O)CNC(=O)CCCCC[N+](C)(C)C
Results by area

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Trials and papers
Status and safety
Data